Unresponsiveness of Experimental Canine Leishmaniosis to a New Amphotericin B Formulation

Study of the toxicity of a new lipid complex formulation of amphotericin B.

OBJECTIVES The aim of this study was to evaluate the toxicity of a new lipid complex formulation of amphotericin B (LC-AmB) produced by a simple process. METHODS Toxicity was evaluated after daily administration for 21 consecutive days in female CD1 mice. Doses of LC-AmB up to 20 mg/kg were used, and compared with Fungizone at 0.5 mg/kg and Abelcet at 10 mg/kg. Acute toxicity after a single b...

formulation and in vitro characterization of amphotericin b

Seroepidemiology of Canine Visceral Leishmaniosis in Kerman City, 2011

Background & Aims: Visceral leishmaniosis (VL) is a sporadic disease in many provinces of Iran, while it is considered endemic in other parts. This study was designed to assess the seroprevalence of canine VL in the Kerman city. Methods: Samples were randomly selected from the referred household dogs to the veterinary hospital of Shahid Bahonar university, Kerman, Iran and stray dogs, eutha...

Stimulation of human and canine neutrophil metabolism by amphotericin B.

The effect of an antifungal agent, amphotericin B, on human and canine neutrophil metabolism was studied. Commercial preparations of amphotericin B in concentrations ranging from 5 to 100 micrograms/ml stimulated neutrophil chemiluminescence in the presence of 10(-8) M luminol. This response was blocked by 2-deoxyglucose, a metabolic inhibitor, and by the absence of extracellular calcium ions. ...

Review articles Canine leishmaniosis – an emerging disease

Canine leishmaniosis (CanL) is an invasive disease of dogs, caused by Leishmania spp. parasites transmitted by the bite of an infected phlebotomine sand fly. CanL is declared an important disease by World Organisation for Animal Health (OIE). Due to its zoonotic potential is of a great importance the prevention of this disease in non endemic areas. Canine leishmaniosis is endemic disease in mor...